Men with advanced Pca who have evidence of progressive disease, such as an increase in serum PSA, new metastases, or progressive existing metastases during ADT, and who have castration levels of serum testosterone (<50 ng/dL), are considered to have CRPC. Here, KLK3 is linked to posterior cortical atrophy.